Abstract-Women are especially predisposed to development of arterial stiffening secondary to obesity because of consumption of excessive calories. Enhanced activation of vascular mineralocorticoid receptors impairs insulin signaling, induces oxidative stress, inflammation, and maladaptive immune responses. We tested whether a subpressor dose of mineralocorticoid receptor antagonist, spironolactone (1 mg/kg per day) prevents aortic and femoral artery stiffening in female C57BL/6J mice fed a high-fat/high-sugar western diet (WD) for 4 months (ie, from 4-20 weeks of age). Aortic and femoral artery stiffness were assessed using ultrasound, pressurized vessel preparations, and atomic force microscopy. WD induced weight gain and insulin resistance compared with control diet-fed mice and these abnormalities were unaffected by spironolactone. Blood pressures and heart rates were normal and unaffected by diet or spironolactone. Spironolactone prevented WD-induced stiffening of aorta and femoral artery, as well as endothelial and vascular smooth muscle cells, within aortic explants. Spironolactone prevented WD-induced impaired aortic protein kinase B/endothelial nitric oxide synthase signaling, as well as impaired endothelium-dependent and endothelium-independent vasodilation. Spironolactone ameliorated WD-induced aortic medial thickening and fibrosis and the associated activation of the progrowth extracellular receptor kinase 1/2 pathway. Finally, preservation of normal arterial stiffness with spironolactone in WD-fed mice was associated with attenuated systemic and vascular inflammation and an anti-inflammatory shift in vascular immune cell marker genes. Low-dose spironolactone may represent a novel prevention strategy to attenuate vascular inflammation, oxidative stress, and growth pathway signaling and remodeling to prevent development of arterial stiffening secondary to consumption of a WD. (Hypertension. 2015;66:99-107.
I
n the setting of obesity and diabetes mellitus, women exhibit significant cardiovascular disease (CVD) more frequently and with higher severity than diabetic men. 1, 2 This is in contrast to lean nondiabetic premenopausal women that have lower incidences of CVD relative to similar men. Increased aortic stiffness independently predicts future CVD, especially in women. 3, 4 Aortic stiffening, which is a normal aging phenomenon, is inordinately deleterious in postmenopausal women compared with men. 5, 6 Moreover, women struggling from obesity have elevated arterial stiffness and are more vulnerable to CVD compared with men. [7] [8] [9] Epidemiological studies reveal that measurement of aortic stiffness has a superior predictive value for determining CV risk compared with classical CV risk factors and, as such, has emerged as an important biomarker predictive of end organ damage and overall CVD risk. 3, 4 Given the ongoing epidemic of obesity, targeting arterial stiffness to reduce the risk for a first CV event 10, 11 with pharmacological or lifestyle interventions is urgently needed, especially for women. Importantly, few studies address the impact of important environmental factors, such as diet, in the genesis of CVD in females. This has led to a call by the National Institutes of Health and the American Heart Association to fill this void with more studies on CVD in females.
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and MR signaling in development of arterial stiffness has emanated from multiple studies. [17] [18] [19] [20] A recent clinical study reported an association between elevated serum aldosterone concentrations and increased aortic stiffening in normotensive overweight and obese adults aged 20 to 45 years. 21 Moreover, accumulating evidence suggests improvement in arterial elasticity occurs with administration of MR antagonists (MRA). [22] [23] [24] Obesity-related vascular insulin resistance promotes endothelial cell (EC) dysfunction as a consequence of impaired insulin-mediated activation of endothelial nitric oxide synthase (eNOS) to reduce bioavailability of nitric oxide (NO). 25 In obesity, impaired EC-mediated vascular relaxation could also result from MR signaling-mediated increased generation of reactive oxygen species with subsequent NO scavenging and reduction in bioavailable NO, which normally reduces extracellular matrix remodeling and stiffening. 14, 15 In addition, abnormal immune and inflammatory responses contribute to vascular dysfunction and stiffness. 21 Extracellular matrix remodeling underlies age-related aortic stiffening. 10, 26 We recently reported that low-dose spironolactone administered to female mice prevents Western diet (WD)-induced development of myocardial stiffness and diastolic dysfunction. 27 That study demonstrated an important role for the MR in promoting myocardial oxidative stress, fibrosis, and impaired immunity associated with decreased left ventricular compliance resulting from consumption of a WD. The idea that an increase in vascular stiffness secondary to consumption of a WD can be mediated by excessive MR signaling is intriguing and raises the question whether using a low (subpressor) dose of an MRA could improve compliance in conduit and muscular arteries (eg, aorta and femoral artery). To test this hypothesis, we administered a low dose of the MRA, spironolactone to female C57BL/6J mice fed a WD high in fat and the refined sugars, sucrose, and high-fructose corn syrup (HFCS). Herein, we report that vascular MR signaling plays an important role in inflammatory and immune responses and development of aortic and femoral artery stiffening secondary to consumption of a WD. Importantly, the development of these CV abnormalities can be prevented with a low dose of spironolactone.
Methods
For detailed description of procedures, see Methods in the onlineonly Data Supplement.
Results

WD-Induced Increases in Body and Fat Pad Weights and Systemic Insulin Resistance Were Not Prevented by Spironolactone
Body weights of 20-week-old WD control (WDC) and WD spironolactone (WDSp) mice were similarly heavier compared with their lean counterparts (Table S1 in the online-only Data Supplement). Percent body weight gain at the end of the study period was 71±8% and 97±12% for control diet control (CDC) and WDC (P=0.06), respectively, and 74±7% and 98±7% for CD spironolactone (CDSp) and WDSp (P<0.05), respectively, and weight gain was unaffected by spironolactone. Perireproductive and retroperitoneal fat pad masses were ≈3-and 2-fold higher in WDC versus CDC (P<0.01), respectively, and these changes were not altered by spironolactone (data not shown). Systemic glucose homeostasis, evaluated by intraperitoneal glucose tolerance, was impaired after WD feeding. The area under the curve of the glycemic excursion after the intraperitoneal glucose challenge was increased in WD-fed mice versus CD-fed mice (P<0.05; Figure S1 ). The area under the curve was unaffected by spironolactone in WD-fed mice.
Spironolactone Prevents WD-Induced Increases in Aortic Pulse Wave Velocity
In vivo pulse wave velocity (PWV), determined in mice after 2 and 3 months on CD or WD ( Figure 1A ; Table S2 ), was unaffected by diet or spironolactone; however, both WD and Sp affected PWV significantly at the 4-month time point. PWV was elevated in the WDC group compared with CDC (P=0.006) and Sp prevented the elevation in PWV (P<0.001). Mean arterial pressure and heart rate were not different among groups at the end of the study ( Figure 1B ).
Spironolactone Prevents WD-Induced Increases in Aortic EC and Vascular Smooth Muscle Cell Stiffness
To determine whether intact EC and vascular smooth muscle cell (VSMC) stiffened in response to WD, we measured surface mechanical stiffness of EC and VSMC in aortic explants using atomic force microscopy ( Figure 1C-1H ). Both EC and VSMC exhibited an ≈5-fold increase in surface stiffness (P<0.05, CDC versus WDC), and these effects were prevented by spironolactone administration (P<0.05 for WDC versus WDSp and P>0.05 for CDC versus WDSp).
Spironolactone Prevents WD-Induced Endothelial Dysfunction in the Aorta
Endothelium-dependent vasodilatory responses to acetylcholine were decreased in WDC compared with CDC (E max =16.3±2.7%, n=4 versus 35.1±2.2%, n=6 and 4, respectively), and these defects were prevented in the WDSp group (E max =29.8±1.8% n=4; Figure 1I ). Similarly, endotheliumdependent vasodilatory responses to insulin were also impaired in WDC mice (E max =34.8±6.5% versus 86.1±1.7%; n=6 and 4, respectively), and improved in the WDSp group (E max =64.2±5.4%, n=4; Figure 1J ). Endothelium-independent vasodilatory responses to sodium nitroprusside were also decreased in WDC compared with CDC (E max =18.7±0.7%, n=4 versus 38.9±2.7%, n=6 and 4, respectively), and these defects were abolished in the WDSp group (E max =35.7±2.6%, n=4; Figure 1K ). Collectively, these data are consistent with improved aortic EC and VSMC function in WDSp animals.
Spironolactone Ameliorates WD-Induced Aortic Remodeling
The medial layer of the aorta was 18% thicker in WD-fed mice compared with CD-fed mice (P<0.01) and thickening was prevented by spironolactone treatment (Figure 2A ; P<0.05, WDC versus WDSp). Adventitial collagen accumulation was significantly enhanced in WD relative to CD-fed mice and this accumulation was prevented by spironolactone treatment ( Figure 2B and 2C) . Fibronectin accumulated predominately in the adventitia in all groups; however, compared with CD, WD induced an increase in adventitial fibronectin and spironolactone prevented this abnormality ( Figure 2D ). Figure 2E ). Staining was most intense in the endothelium, modest in the adventitia, and relatively minimal in the medial layer. Spironolactone largely prevented 3-nitrotyrosine accumulation in the endothelium and adventitia (P<0.05, WDC versus WDSp for both layers).
Spironolactone Prevented WD-Induced Activation of ERK1/2 and Impairment in Protein Kinase B (Akt)/eNOS in the Aorta WD induced a 3-fold increase in ERK1/2 activation (P<0.05, CDC versus WDC) that was prevented by spironolactone (P<0.05, WDC versus WDSp; Figure 3A ). WD induced decreases in the phosphorylation (p) of both p-Akt Ser473 and p-eNOS Ser1177 in aorta protein extracts compared with those from CDC mice (P<0.05 for both proteins; Figure 3B and 3C).
Spironolactone preserved the normal activation levels in both p-Akt Ser473 and p-eNOS Ser1177 protein compared with WDC group (P<0.05 for each protein).
Spironolactone Ameliorates Immune and Inflammatory Changes in the Aorta
Inflammatory Markers
Levels of the proinflammatory M1 marker transcripts, monocyte chemoattractant protein-1 and CD 86, were elevated in aortic extracts of WDC and WDSp versus CDC mice ( Figure 4A ). The transcript level of interleukin (IL)-10, an anti-inflammatory M2 marker, was elevated only in WDSp. The ratios of M2 to M1 expression illustrates that there was a relative increase in macrophage polarization favoring M2 in the WDSp group compared with WDC ( Figure 4B ). In addition, the aorta of WDC mice exhibited significantly elevated levels of the macrophage marker, CD11b, which was not affected by spironolactone. Nonetheless, there was a relative increase in macrophage polarization favoring M2 in the differences were found for the endothelium-independent vasodilatory responses to sodium nitroprusside between any of the groups ( Figure 5C ).
Effects of Spironolactone and Diet on Femoral Artery Structure
Femoral arteries from WD-fed mice were less distensible than those of CD-fed mice as indicated by a significant leftward shift in their circumferential wall stress-strain curves ( Figure 5D ). Femoral arteries of WDSp mice were significantly more distensible than those of WDC. The modulus of elasticity, used as an index of stiffness, was significantly elevated in femoral arteries of WDC mice compared with those of CDC and WDSp ( Figure 5E ). No significant differences were observed for the internal passive pressure-diameter relationships, an index of remodeling, or were there differences in wall/lumen ratios, mean wall thickness, and wall cross-sectional areas between any of the groups (Figure 5F-5I).
Discussion
Collectively, the results of this investigation support the hypothesis that MR plays an important role in the development of aortic stiffness in female mice in the setting of WD-induced insulin resistance. Herein, we demonstrate that aortic PWV is increased in female mice fed a diet high in fat and refined sugars (sucrose/HFCS). Although MR blockade had no effect on reducing excess body or fat pad weight, it completely prevented the increase in PWV observed in the untreated mice fed WD. Atomic force microscopy was used to further assess potential cellular contributions to aortic stiffness using ex vivo aortic explants to measure EC and VSMC stiffness. Intact explants enable measurement of stiffness of EC and VSMC that are still in contact with native extracellular matrix proteins. Our findings in both types of preparations identified abnormally high stiffness in WD-fed mice that was prevented with spironolactone.
Abnormalities in the insulin signaling cascade in the aorta, including decreased Akt activation, have been documented in models of obesity and insulin resistance. 28, 29 In this study, we observed decreased vascular Akt phosphorylation (activation) in untreated WD-fed mice compared with their CD-fed counterparts. We also examined phosphorylation of eNOS as a downstream target of insulin-Akt signaling. Compared with untreated mice fed CD, we observed a marked decrease in phosphorylated eNOS 1177 and the ratio of p-eNOS 1177 /total eNOS in WD-fed female mice. Therefore, decreased eNOS phosphorylation may account, in part, for the impairment of aortic endothelial function and this may contribute to the observed aortic stiffening. A recent study indicated that aldosterone contributes importantly to a phenomenon known as stiff endothelial cell syndrome mediated by increased EC expression of the epithelial sodium channel and MR in concert with impaired generation of NO, and that spironolactone can prevent its manifestation and improve endothelial function. 22 Therefore, therapies that increase EC NO bioavailability and improve EC function could potentially reduce aortic stiffening in overweight individuals. 11 Inflammation because of maladaptive immune responses has recently been implicated in playing a role in development of vascular disease, including vascular stiffness. 15, 30 One of the immune mechanisms related to inflammation is polarization of macrophages. 25 The activation of an M1 macrophage phenotype leads to a proinflammatory response and conversely, activation of M2 macrophages mount an opposing anti-inflammatory response. Nonetheless, no studies have linked consumption of a high fat/high sucrose/HFCS diet with aortic stiffening, dysfunction and remodeling, and an abnormal immune and inflammatory response and macrophage polarization. We observed increases in monocyte chemoattractant protein-1, and CD86 in the aorta of WD-fed mice suggestive of an inflammatory response. Even though spironolactone did not prevent the WD-induced increase in these proinflammatory markers, it significantly increased the M2 macrophage marker, IL-10, leading to improvement in the M1/M2 ratio suggesting suppression of the inflammatory response. Recent evidence indicates that IL-10 may contribute to improved cardiovascular insulin sensitivity. In addition, IL-10 released from regulatory T cells has also been shown to improve endothelial function by suppressing NADPH oxidase-mediated oxidative stress. 32 Therefore, the apparent improvement in M2 macrophage polarization observed in this study may contribute to prevention of vascular injury by MR blockade. Although insulin metabolic signaling through Akt/eNOS pathway is impaired, growth factor signaling through activation of ERK1/2 pathway is either not affected or stimulated.
14 In this regard, ERK1/2 activation modulates vascular remodeling and inflammatory response.
14 Thus, ERK activation may contribute to vascular inflammation, remodeling, and arterial stiffness, as observed in this study.
In addition to the aorta, we also examined the function and structure of the femoral artery. As established by the recent Hoorn study, local arterial stiffness measures, specifically in the femoral and carotid arteries, but not brachial artery, independently predict CVD risk. 33 This is the first study to show that WD feeding results in impairments in femoral artery distensibility and stiffness and that low-dose MRA prevents these impairments. In this study, endothelium-dependent and endothelium-independent vasodilatory responses to acetylcholine and sodium nitroprusside in the femoral artery were not affected by WD feeding, but spironolactone treatment significantly enhanced endothelial-dependent vasodilation in femoral arteries ( Figure 5 ). In this study, we have used a low dose of spironolactone, and the rationale for this is 3-fold. First, we previously established that this dose does not affect blood pressure. 34 Second, in addition to the MR, spironolactone binds to androgen, progesterone, and glucocorticoid receptors; however, binding to non-MR is likely to require much higher doses of spironolactone to induce antiandrogenic or progesterone actions. 35 Finally, addition of low dose of a MRA to standard therapy has been shown to reduce morbidity and mortality among patients with heart failure. 36 Thus, it could be reasoned that addition of low-dose MRAs could prevent further progression of vascular stiffening and the associated risk of heart failure in obese females regardless of diabetic status and with minimal risk of side effects. Moreover, it is likely that the antistiffening effects of MRAs relate largely to preventing aldosterone because opposed to glucocorticoid-mediated MR signaling in the vasculature. This is because both vascular endothelial and smooth muscle cells express 11-β hydroxysteroid dehydrogenase, an enzyme that limits glucocorticoid signaling through the MR receptor. 37 In contrast to our study, others have reported resistance to the metabolic and CV complications associated with highfat diets in female mice, 38 suggesting estrogen-mediated CV protection. 39 Such studies have mostly used high-fat diets rather than diets high in both fat and refined sugars like the diet used in this investigation. The abrogation of CV protection manifested in our model as an increase in aortic stiffness is consistent with clinical studies reporting increases in aortic PWV in overweight women. 40, 41 Data from the Framingham Heart Study indicate that women have higher serum aldosterone concentrations that correlate with a pattern of left ventricular concentric remodeling. 16 We previously reported that young female C57BL6 mice exhibit higher serum levels of aldosterone compared with males (≈50% higher in females), but WD had no effect on aldosterone levels in males or females. 7 Therefore, we speculate that the interaction of higher aldosterone levels in females and consumption of a WD high in fat, sucrose, and HFCS may act synergistically to promote the observed increases in oxidative stress, inflammation, and vascular stiffness. However, a recent in vitro study showed that estrogen can suppress aldosterone-mediated expression of genes in EC that contribute to CV dysfunction and disease. 42 Thus, it is possible that this antagonistic effect of estrogen on deleterious MR signaling in the vasculature may be abrogated with high fat/ sucrose/HFCS diet.
The results of this study indicate that the effects of spironolactone on prevention of WD-induced vascular stiffness occurred in the absence of an increase in mean arterial pressure and HR. Moreover, aortic stiffness was not increased in control mice at the end of the feeding trial, therefore, the effects seen in WD are not because of normal aging processes. The potential influence of the female estrous cycle on PWV is a potential limitation of this study. Nonetheless, a previous report demonstrated that PWV does not vary over the course of the menstrual cycle in women. 43 In conclusion, we have elucidated a role for the MR in development of aortic stiffness and the associated abnormalities in immune responses, oxidative stress, endothelial/smooth muscle function, and structural remodeling in a clinically relevant female model of weight gain because of consumption of a WD high in fat, HFCS, and sucrose. Importantly, aortic stiffness was detected not only in vivo, but also on the aortic EC and VSMC surfaces of ex vivo preparations. These findings may be particularly relevant to overweight and obese women who may be at increased risk for development of aortic stiffness and CVD.
Perspectives
Results of this investigation suggest not only that MR play a critical role in development of WD-induced aortic stiffness, but also that a low dose of spironolactone exerts profound prophylaxis to maintain vascular health in individuals consuming a high fat/sucrose/HFCS diet. Targeting the MR with adjunctive low-dose spironolactone may be an effective strategy to limit vascular disease progression in individuals struggling from overweight/obesity that are at risk for a first CV event. Our results suggest that this strategy could minimize the likelihood of side-effects associated with spironolactone (hypokalemia or hypotension) and maximize the efficacy of MRA. Thus, the rationale for this strategy parallels the rationale for use of a low dose of spironolactone to treat severe heart failure reported in Randomized Aldactone Evaluation Study (RALES). 15 Running Title: Mineralocorticoid blockade ameliorates aortic stiffness 13 14 *contributed equally to this work 15 16 Co-corresponding Authors: 
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Animal Models
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Three week old C57BL/6J female mice (stock number 00664) were procured from Jackson Laboratories
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(Bar Harbor, ME). All procedures were approved in advance by the Institutional Animal Care and Use begins to rise at the start of systole. The distance between the two locations along the aorta is divided by 68 the difference in arrival times and is expressed in m/s. Velocity waveforms were acquired at the aortic 69 arch followed immediately by measurement at the descending aorta 35 mm distal to the aortic arch.
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Ultrasound procedures were performed on isoflurane-anesthetized mice (1.75% in 100% oxygen 71 stream).
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Blood Pressure
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While under isoflurane (1.75% isoflurane in 100% O 2 ) anesthesia, the right carotid artery was 
Preparation of enface ex vivo Aortic Explants for AFM
79
To evaluate the stiffness of EC and VSMC in aortic preparations a 2x2 mm segment of the thoracic aorta Where, E is the E-modulus, F is the force exerted by AFM probe on tissue surface, δ is indentation 
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Vascular functional parameters were evaluated in the aorta and femoral arteries from the same mice. that constricted more than 20% to this 80 mM K + solution were used in the analyses.
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After the exposure to high K + , the arteries were washed three times with fresh PSS containing (in Total RNA was isolated from thoracic aorta extracts using TRIzol reagent (Sigma). RNA yield was 148 determined using a Nanodrop spectrophotometer (Thermo Scientific, Wilmington, DE). First-strand 149 cDNA synthesis and real-time PCR was performed as previously described. 13 The primer sequences for 
